[(1S,2R,3S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(3-sulfanylpropanoyl)amino]propanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: [(1S,2R,3S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(3-sulfanylpropanoyl)amino]propanoate
• 化学式: C₃₅H₄₈ClN₃O₁₀S
• 分子量: 738.3
• InChiKey: ANZJBCHSOXCCRQ-SOWBYDQGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  50
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Anti-IL1RAP antibodies and antibody drug conjugates
  申请人：Bluefin BioMedicine, Inc.

  公开号：US11248054B2

  公开（公告）日：2022-02-15

  Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  本文公开了白细胞介素 1 受体附属蛋白（IL1RAP）抗体和抗体药物共轭物（ADC），包括使用所述抗体和 ADC 的组合物和方法。
• PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
  申请人：ABBVIE INC.

  公开号：US20140227294A1

  公开（公告）日：2014-08-14

  The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
• ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：ABBVIE INC.

  公开号：US20150337042A1

  公开（公告）日：2015-11-26

  The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
• ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：Bluefin BioMedicine, Inc.

  公开号：US20200140561A1

  公开（公告）日：2020-05-07

  Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
• US9493568B2
  申请人：——

  公开号：US9493568B2

  公开（公告）日：2016-11-15